The platform addresses a massive market opportunity at the intersection of the $28.65B global weight loss supplement market and the $39.74B global probiotic drink market, with initial focus on the U.S
ATM also phosphorylates multiple downstream targets (notably including, p53, -H2AX, CHK1 and CHK2) that are also involved in apoptosis, cell cycle regulation and DNA repair 47,48,49
You can reach us via phone (202-251-4472) or through our website today.
Acknowledgements Medical writing and editorial support were provided by Nicole Cash, PhD, and Abbey Pearson, MSci, of Axis, a division of Spirit Medical Communications Group Limited (and were funded by Novo Nordisk Inc.) in accordance with Good Publication Practice 3 (GPP3) guidelines ( Ethics declarations Funding This trial and medical writing support for the publication were funded by Novo Nordisk A/S, Sborg, Denmark